Abstract
Pituitary adenomas (PAs) are common, usually benign tumors of the anterior pituitary gland which, for the most part, have no known genetic cause. PAs are associated with major clinical effects due to hormonal dysregulation and tumoral impingement on vital brain structures. Following the identification of a loss-of-function variant (p.Arg703Gln) in the PAM gene in a family with pituitary gigantism, we investigated 299 individuals with sporadic PAs and 17 familial isolated pituitary adenomas kindreds for PAM variants. PAM encodes a multifunctional protein responsible for the essential C-terminal amidation of secreted peptides.
Genetic screening was performed by germline and tumor sequencing and germline copy number variation (CNV) analysis. No germline CNVs or somatic single nucleotide variants (SNVs) were identified. We detected seven likely pathogenic heterozygous missense, truncating, and regulatory SNVs. These SNVs were found in sporadic subjects with GH excess (p.Gly552Arg and p.Phe759Ser), pediatric Cushing disease (c.-133T>C and p.His778fs), or with different types of PAs (c.-361G>A, p.Ser539Trp, and p.Asp563Gly). The SNVs were functionally tested in vitro for protein expression and trafficking by Western blotting, for splicing by minigene assays, and for amidation activity in cell lysates and serum samples. These analyses confirmed a deleterious effect on protein expression and/or function. By interrogating 200,000 exomes from the UK Biobank, we confirmed a significant association of the PAM gene and rare PAM SNVs to diagnoses linked to pituitary gland hyperfunction.
Identification of PAM as a candidate gene associated with pituitary hypersecretion opens the possibility of developing novel therapeutics based on altering PAM function.
Competing Interest Statement
Dr. Beckers, Dr. Daly, Dr. Faucz, Dr. Stratakis and Dr. Trivellin hold a patent on the GPR101 gene and its function (US Patent No. 10,350,273, Treatment of Hormonal Disorders of Growth). Dr. Stratakis holds patents on technologies involving PRKAR1A and related genes causing adrenal, pituitary, and other tumors. In addition, his laboratory has received research funding support by Pfizer Inc. for investigations on growth-hormone producing pituitary adenomas. Dr. Stratakis also has consulted within the last 12?months with Lundbeck Pharmaceuticals and Sync, LLC, and is currently employed by ELPEN Pharmaceuticals. Dr. Beckers and Dr. Daly have received research funding from Pfizer Inc. and Novo-Nordisk. Dr. Jaffrain-Rea is part of the advisory board of Recordati Rare diseases since 2022. The authors declare that they have no conflicts of interest with the contents of this article.
Funding Statement
The work was supported by the following funding sources: Society for Endocrinology equipment grant (to GT), Intramural Research Program, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH) Research projects Z1A HD008920 (to CAS, supporting GT, LCHR, FRF), R01-DK032949 (to BAE and REM), the Intramural Research Program of the National Human Genome Research Institute (to CT and WAG), the Daniel Schwartzberg Fund (to REM and BAE), Fonds d Investissement pour la Recherche Scientifique (FIRS) of the Centre Hospitalier Universitaire de Liege (to AFD and AB), Novo Nordisk Belgium Educational Grant, Belgium (to AFD and AB), the JABBS Foundation, UK (to AB). AFD was supported, in part, by Action de Recherche Concertee (ARC) Grant 17/21-01 from Liege University.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Undiagnosed Diseases Program (UDP) patients provided written informed consent under clinical protocol 76-HG-0238, Diagnosis and Treatment of Patients with Inborn Errors of Metabolism and Other Genetic Disorders, approved by the National Human Genome Research Institute (NHGRI) Institutional Review Board. Other individuals from the National Institutes of Health (NIH) were recruited between 1997-2017 under research protocol 97-CH-0076 (ClinicalTrials.gov: NCT00001595). The study was approved by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Institutional Review Board and by the Ethics Committee of the University of Liege, Belgium. Affected subjects or their relatives signed informed consent or assent forms approved by the local ethics committee. Parents and siblings of the affected individuals were also recruited, when appropriate and available. The UK Biobank (UKBB) obtained ethics approval from the North West Multi-centre Research Ethics Committee (approval number: 11/NW/0382) and obtained informed consent from all participants.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
